Minimal clinically important differences in health-related quality of life after treatment with direct-acting antivirals for chronic hepatitis C: ANRS CO22 HEPATHER cohort (PROQOL-HCV)

ConclusionsThe overall MCID for the PROQOL-HCV scores ranged from 6.7 to 8.8 for improvement and from − 7.7 to − 4.6 for deterioration. The effect of DAA on PROQOL-HCV scores seemed particularly beneficial for patients with lower baseline scores. This subgroup could be motivated to take DAA if they are informed of the benefits for their HRQoL.
Source: Quality of Life Research - Category: Health Management Source Type: research